Products Affected - Description

• • Transderm Scop transdermal system, Baxter, 1.5 mg (1 mg/3 days), 10 count, NDC 10019-0553-03
  • Transderm Scop transdermal system, Baxter, 1.5 mg (1 mg/3 days), 24 count, NDC 10019-0553-04
  • Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 10 count, NDC 00591-2258-79
  • Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 24 count, NDC 00591-2258-23

Reason for the Shortage

• • Baxter has Transderm Scop patches on shortage due to manufacturing delays.
  • Ingenus has scopolamine transdermal patches available.
  • Padagis has scopolamine transdermal patches available.
  • Rhodes has scopolamine transdermal patches available.
  • Teva did not provide a reason for the shortage.
  • Viatris has scopolamine transdermal patches available.
  • Zydus has scopolamine transdermal patches available.

Available Products

• • Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 4 count, NDC 50742-0505-04
  • Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 10 count, NDC 50742-0505-10
  • Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 24 count, NDC 50742-0505-24
  • Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 4 count, NDC 00378-6470-99
  • Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 10 count, NDC 00378-6470-97
  • Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 24 count, NDC 00378-6470-44
  • Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 4 count, NDC 45802-0580-84
  • Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 10 count, NDC 45802-0580-46
  • Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 24 count, NDC 45802-0580-62
  • Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 4 count, NDC 42858-0150-40
  • Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 10 count, NDC 42858-0150-14
  • Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 24 count, NDC 42858-0150-70
  • Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 4 count, NDC 00591-2258-04
  • Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 4 count, NDC 70710-1846-04
  • Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 10 count, NDC 70710-1846-02
  • Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 24 count, NDC 70710-1846-07

• • Baxter has Transderm Scop 1.3 mg patches on back order and the company estimates a release date in the fourth quarter of 2025.
  • Teva has scopolamine 1.3 mg patches in 10 count and 24 count on back order and the company estimates a release date in mid-November 2025.

• • Labeled indications for scopolamine transdermal include the prevention of motion sickness and the prevention of postoperative nausea and vomiting.[1-2]
  • Off-label indication for the scopolamine patch includes the reduction secretions at end of life.[1-2]

• • Apply scopolamine transdermal system behind the ear the evening before or at least 2 hours prior to surgery.[1,3]
  • Only wear 1 scopolamine transdermal patch at a time. Do not cut the transdermal system. Avoid pressure on the transdermal system following application to avoid scopolamine release outside the transdermal system.[1]
  • Consider a trial dose of any medication used to prevent or treat motion sickness due to potential side effects.[4]

• • Postoperative nausea and vomiting alternative agents and management
  • There are no other transdermal systems recommended for the prevention of postoperative nausea and vomiting.[3]
  • There are numerous oral and intravenous medications (eg, dexamethasone, ondansetron) recommended to treat postoperative nausea and vomiting. The time of administration varies from the start of surgery to end of surgery. Combination of medications may also be considered.[3]
  • Motion sickness alternative agents and management
  • Nonpharmacologic management of motion sickness includes controlled breathing, avoidance of head movements, avoidance of reading, among other measures.[4] For optimal effect, pairs behavioral interventions with pharmacologic intervention.[5]
  • There are no other transdermal systems recommended for the prevention of motion sickness.[4]
  • Meclizine and diphenhydramine may be used for the prevention of motion sickness, but these medications are not as effective as scopolamine transdermal.[5]

• 1. Scopolamine [prescribing information]. Parsippany, NJ: Actavis Pharma Inc.; June 2025.
  2. Scopolamine. Lexicomp Online. Wolters Kluwer Clinical Drug Information. Hudson, Ohio, USA. Accessed September 7, 2025.
  3. Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2020;131(2):411-48.
  4. Motion sickness. Centers for Disease Control Yellow Book. Updated April 23, 2025. Accessed September 10, 2025. https://www.cdc.gov/yellow-book/hcp/travel-air-sea/motion-sickness.html
  5. Brainard A and Gresham C. Prevention and treatment of motion sickness. Am Fam Physician. 2014;90(1):41-6.